Manish Patel, DO, discussed the unmet needs that led to the investigation of ADT plus pembrolizumab in patients with advanced salivary gland carcinoma.
Dr Patel on the BTCRC HN17-111 Trial of ADT Plus Pembrolizumab in Salivary Gland Cancer
Manish Patel, DO, discussed the single-arm BTCRC HN17-111 study investigating ADT plus pembrolizumab in advanced, AR-positive salivary gland cancer.
Manish Patel, DO, discusses response rates seen with ADT in combination with pembrolizumab in advanced, androgen receptor–positive salivary gland cancer.
Manish Patel, DO, discusses AEs seen with ADT plus pembrolizumab in patients with advanced-stage, androgen receptor–positive salivary gland cancer.
Manish Patel, DO, discusses future directions for investigating hormonal plus immune therapies for the treatment of patients with salivary gland cancer.
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
5